For Oncology Nurses: Strategies to Safely and Effectively Implement Antibody-Drug Conjugates — Proceedings from the 2026 Annual ONS Congress

Hello, everyone, and welcome to Recent Advances in Cancer Care, New Paradigms, Novel Agents, and What it Means for the Oncology Nurse, Strategies to Safety and Effectively Implement Antibody Drug Conjugates.

I'm Dr. Kathleen Moore, and I'll be moderating the meeting today.

This is our faculty for today.

I'm going to briefly introduce them, and they can wave and say hello.

From the James Cancer Hospital at The Ohio State University, Courtney Arnn.

From Mayo Clinic, Jamie Carroll.

From the David Geffen School of Medicine, Dr. Eddie Guerin.

And from the UT Southwestern Medical Center, Dr. Heather MacArthur.

These are just our disclosures.

I'm going to flip through these relatively quickly so you can see.

And these are all available for you in the meeting materials.

Here's the commercial support for today.

Research to Practice CME Planning Committee staff and reviewers have no COI to disclose.

This program will contain disclosures of non-approved uses of agents and regimens, so please refer to official prescribing information for each product for approved indications.

The education themes of all 11 programs focus on the integration of new agents, regimens, and therapies into oncology practice, when they should be used, for whom, and why, as well as how to prevent and manage associated side effects.

So this is just what we're going to be doing today.

And this is where we're headed today.

We'll start out with an overview of antibody drug conjugates.

Then we'll discuss HER2-targeted antibody drug conjugates in breast cancer, followed by a review of available antibody drug conjugates in gynecologic cancers, then lung cancer.

Then we'll focus on TROP2 in breast cancer and spend the last portion of the program talking about promising new antibody drug conjugates in gynecologic and lung cancers.

So with that, let's get started.

We have a lot to cover.

And so I'm just going to open up the discussion to my panel right now.